Lupin looks set to avoid largely an antitrust lawsuit stemming from allegations it conspired with the former Valeant Pharmaceuticals company to delay the launch of a generic version of the Canadian firm’s Glumetza (metformin) and subsequently enjoy engorged profits, after reaching a settlement agreement worth $248m with a class of purchasers and retailers.
The Indian firm, which announced the settlement just days after Bausch Health announced a $300m settlement deal over its part in the alleged scheme, is due to face trial over certain claims on 4
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?